What does CARO PHARMA do?

CARO PHARMA is a pharmacy in Erquelinnes. Private Limited, started on 17 July 2008, 1 establishment.

What is the address of CARO PHARMA?

The registered office of CARO PHARMA is located at Mont de Solre 24, 6560 Erquelinnes.

Is CARO PHARMA still active?

Yes. According to the CBE (30 October 2026) CARO PHARMA is active, legal situation “Normale toestand”, started on 17 July 2008.

Is CARO PHARMA registered on Peppol?

Yes, CARO PHARMA is registered on the Peppol network with ID 0208:0899338864.

What is the enterprise number of CARO PHARMA?

The enterprise number of CARO PHARMA is BE0899338864.

When was CARO PHARMA founded?

CARO PHARMA was founded on 17 July 2008.

Who are the directors of CARO PHARMA?

According to the 2025 annual accounts, the directors of CARO PHARMA are: Olivier Petit.

Is CARO PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 17 July 2008; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did CARO PHARMA make in 2025?

CARO PHARMA recorded a loss after taxes of € 26,056 in financial year 2025.

What is the revenue of CARO PHARMA?

As a small company, CARO PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 81,453.

CARO PHARMA (Private Limited) - Erquelinnes

Dossier CARO PHARMA, printed on 30 October 2026 from databakkes.be/en/0899338864/caro-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.
Tight liquidity NBB

Cash and receivables cover 42 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

CARO PHARMA from Erquelinnes, company number BE0899338864, closed financial year 2025 with a result of € -26,056 after tax. For that financial year CARO PHARMA recorded a gross margin of € 81,453 and equity of € 154,269. Compared with financial year 2024, the result moved from € -81,990 to € -26,056. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 26, 2026.

What it is worth Healthy

€ 154,269

▼ 14% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -26,056

▲ 68 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 29,891

▲ 12% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 104,269.

Debts at end 2025

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 111,794

▼ 29% vs 2024

€ 46,107 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 69,686

▼ 5% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 35,702

▲ 89% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 114,589 Gross margin 2022: € 114,589 First fiscal year in the series	€ 74,550 Gross margin 2023: € 74,550 ▼ 35% vs 2022 (€ 114,589) Unfavourable step	€ 91,505 Gross margin 2024: € 91,505 ▲ 23% vs 2023 (€ 74,550) Favourable step	€ 81,453 Gross margin 2025: € 81,453 ▼ 11% vs 2024 (€ 91,505) Unfavourable step	▼ 11%
Profit after taxes	€ 18,834 Profit after taxes 2022: € 18,834 First fiscal year in the series	€ 630 Profit after taxes 2023: € 630 ▼ 97% vs 2022 (€ 18,834) Unfavourable step	€ -81,990 Profit after taxes 2024: € -81,990 ▼ € 82,621 vs 2023 (€ 630) Unfavourable step	€ -26,056 Profit after taxes 2025: € -26,056 ▲ € 55,935 vs 2024 (€ -81,990) Favourable step	▲ € 55,935
Equity	€ 261,685 Equity 2022: € 261,685 First fiscal year in the series	€ 262,315 Equity 2023: € 262,315 Unchanged (€ 261,685) Favourable step	€ 180,325 Equity 2024: € 180,325 ▼ 31% vs 2023 (€ 262,315) Unfavourable step	€ 154,269 Equity 2025: € 154,269 ▼ 14% vs 2024 (€ 180,325) Unfavourable step	▼ 14%
Total debts	€ 443,164 Total debts 2022: € 443,164 First fiscal year in the series	€ 393,408 Total debts 2023: € 393,408 ▼ 11% vs 2022 (€ 443,164) Favourable step	€ 388,828 Total debts 2024: € 388,828 ▼ 1% vs 2023 (€ 393,408) Favourable step	€ 339,754 Total debts 2025: € 339,754 ▼ 13% vs 2024 (€ 388,828) Favourable step	▼ 13%
Cash	€ 5,304 Cash 2022: € 5,304 First fiscal year in the series	€ 42,264 Cash 2023: € 42,264 ▲ € 36,961 vs 2022 (€ 5,304) Favourable step	€ 26,783 Cash 2024: € 26,783 ▼ 37% vs 2023 (€ 42,264) Unfavourable step	€ 29,891 Cash 2025: € 29,891 ▲ 12% vs 2024 (€ 26,783) Favourable step	▲ 12%
Land & buildings	€ 166,281 Land & buildings 2022: € 166,281 First fiscal year in the series	€ 158,181 Land & buildings 2023: € 158,181 ▼ 5% vs 2022 (€ 166,281) Unchanged	€ 150,081 Land & buildings 2024: € 150,081 ▼ 5% vs 2023 (€ 158,181) Unchanged	€ 141,981 Land & buildings 2025: € 141,981 ▼ 5% vs 2024 (€ 150,081) Unchanged	▼ 5%
Retained profit	€ 211,685 Retained profit 2022: € 211,685 First fiscal year in the series	€ 212,315 Retained profit 2023: € 212,315 Unchanged (€ 211,685) Favourable step	€ 130,325 Retained profit 2024: € 130,325 ▼ 39% vs 2023 (€ 212,315) Unfavourable step	€ 104,269 Retained profit 2025: € 104,269 ▼ 20% vs 2024 (€ 130,325) Unfavourable step	▼ 20%
Bank debt	€ 192,261 Bank debt 2022: € 192,261 First fiscal year in the series	€ 153,844 Bank debt 2023: € 153,844 ▼ 20% vs 2022 (€ 192,261) Favourable step	€ 157,595 Bank debt 2024: € 157,595 ▲ 2% vs 2023 (€ 153,844) Unfavourable step	€ 111,794 Bank debt 2025: € 111,794 ▼ 29% vs 2024 (€ 157,595) Favourable step	▼ 29%
Balance sheet total	€ 808,230 Balance sheet total 2022: € 808,230 First fiscal year in the series	€ 757,655 Balance sheet total 2023: € 757,655 ▼ 6% vs 2022 (€ 808,230) Unchanged	€ 669,636 Balance sheet total 2024: € 669,636 ▼ 12% vs 2023 (€ 757,655) Unchanged	€ 593,057 Balance sheet total 2025: € 593,057 ▼ 11% vs 2024 (€ 669,636) Unchanged	▼ 11%

Key figures of CARO PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to CARO PHARMA?

What happened at CARO PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 26, 2026 New annual accounts for financial year 2025: loss of € 26,056. Source: NBB ↗
Jul 17, 2008 New establishment in Erquelinnes. KBO
Jul 17, 2008 Start of the company according to the CBE. KBO

In short

From € 18,834 profit in 2022 to € 26,056 loss in 2025.

Paid € 104,482 in corporate taxes since 2022.

Best year ever: 2022, with € 18,834 profit.

Original PDFs at the National Bank ↗

Management

Olivier Petit

CARO PHARMA

Behind CARO PHARMA is Olivier Petit.

Directors

According to the 2025 annual accounts

Olivier Petit

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Mont de Solre 24

6560 Erquelinnes

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0899.338.864
VAT number: BE 0899.338.864
Registered office: Mont de Solre 24, 6560 Erquelinnes
Names & denominations: CARO PHARMA
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 17 July 2008
Peppol: Active · Active since 26 Nov 2025
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗